2 Composition for enhancing immune anticancer effect comprising an alpha 2 adrenergic receptor agonist
The present invention relates to an anti-cancer effect enhancing composition comprising an alpha-2 adrenergic receptor agonist as an active ingredient. More specifically, by confirming the enhancement of anti-cancer effects in which cancer cell-derived exosome secretion is inhibited and PD-L1 expres...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | CHOE EUN JI BAEK MOON CHANG PARK JU MI |
| description | The present invention relates to an anti-cancer effect enhancing composition comprising an alpha-2 adrenergic receptor agonist as an active ingredient. More specifically, by confirming the enhancement of anti-cancer effects in which cancer cell-derived exosome secretion is inhibited and PD-L1 expression inducing immune escape of T cells is inhibited when treating a cancer cell with the composition according to the present invention, the alpha-2 adrenergic receptor agonist may be utilized for developing an anti-cancer effect enhancing formulation for enhancing prevention or treatment of cancer, as an immune checkpoint inhibitor or an inhibitor against cell surface or exosome PD-L1 expression.
본 발명은 알파-2 아드레날린 수용체 효능제를 유효성분으로 포함하는 항암 효과 증진용 조성물에 관한 것으로, 보다 상세하게는 본 발명에 따른 조성물을 암세포에 처리하였을 때에 암세포 유래의 엑소좀 분비가 억제되고, T 세포의 면역 회피를 유도하는 PD-L1의 발현이 억제되는 항암효과가 증진되는 것을 확인함으로써, 알파-2 아드레날린 수용체 효능제를 면역관문 억제제 및 세포 표면 또는 엑소좀 PD-L1의 발현에 대한 억제제로써 암 질환의 예방 또는 치료를 증진할 수 있는 항암 효과 증진용 제제 개발에 유용하게 활용될 수 있다. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_KR20220149444A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>KR20220149444A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_KR20220149444A3</originalsourceid><addsrcrecordid>eNqNjLEKAjEQRK-xEPUfFqyFM6axPA5FsBP7Y1k3uYXLJiTx_43gB1gNzLw3684ZGGNIsUiVqOBiBtYZlUQ9SAhvZUCtQq3itjnHVIGakqV8GVTAJc0IBvCVWTl7IchMnGo7Qx9VSt12K4dL4d0vN93-enmOtwOnOHFJSM2s0_1hemP6oz1ba4fTf9QHRv1AQA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>2 Composition for enhancing immune anticancer effect comprising an alpha 2 adrenergic receptor agonist</title><source>esp@cenet</source><creator>CHOE EUN JI ; BAEK MOON CHANG ; PARK JU MI</creator><creatorcontrib>CHOE EUN JI ; BAEK MOON CHANG ; PARK JU MI</creatorcontrib><description>The present invention relates to an anti-cancer effect enhancing composition comprising an alpha-2 adrenergic receptor agonist as an active ingredient. More specifically, by confirming the enhancement of anti-cancer effects in which cancer cell-derived exosome secretion is inhibited and PD-L1 expression inducing immune escape of T cells is inhibited when treating a cancer cell with the composition according to the present invention, the alpha-2 adrenergic receptor agonist may be utilized for developing an anti-cancer effect enhancing formulation for enhancing prevention or treatment of cancer, as an immune checkpoint inhibitor or an inhibitor against cell surface or exosome PD-L1 expression.
본 발명은 알파-2 아드레날린 수용체 효능제를 유효성분으로 포함하는 항암 효과 증진용 조성물에 관한 것으로, 보다 상세하게는 본 발명에 따른 조성물을 암세포에 처리하였을 때에 암세포 유래의 엑소좀 분비가 억제되고, T 세포의 면역 회피를 유도하는 PD-L1의 발현이 억제되는 항암효과가 증진되는 것을 확인함으로써, 알파-2 아드레날린 수용체 효능제를 면역관문 억제제 및 세포 표면 또는 엑소좀 PD-L1의 발현에 대한 억제제로써 암 질환의 예방 또는 치료를 증진할 수 있는 항암 효과 증진용 제제 개발에 유용하게 활용될 수 있다.</description><language>eng ; kor</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221108&DB=EPODOC&CC=KR&NR=20220149444A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221108&DB=EPODOC&CC=KR&NR=20220149444A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHOE EUN JI</creatorcontrib><creatorcontrib>BAEK MOON CHANG</creatorcontrib><creatorcontrib>PARK JU MI</creatorcontrib><title>2 Composition for enhancing immune anticancer effect comprising an alpha 2 adrenergic receptor agonist</title><description>The present invention relates to an anti-cancer effect enhancing composition comprising an alpha-2 adrenergic receptor agonist as an active ingredient. More specifically, by confirming the enhancement of anti-cancer effects in which cancer cell-derived exosome secretion is inhibited and PD-L1 expression inducing immune escape of T cells is inhibited when treating a cancer cell with the composition according to the present invention, the alpha-2 adrenergic receptor agonist may be utilized for developing an anti-cancer effect enhancing formulation for enhancing prevention or treatment of cancer, as an immune checkpoint inhibitor or an inhibitor against cell surface or exosome PD-L1 expression.
본 발명은 알파-2 아드레날린 수용체 효능제를 유효성분으로 포함하는 항암 효과 증진용 조성물에 관한 것으로, 보다 상세하게는 본 발명에 따른 조성물을 암세포에 처리하였을 때에 암세포 유래의 엑소좀 분비가 억제되고, T 세포의 면역 회피를 유도하는 PD-L1의 발현이 억제되는 항암효과가 증진되는 것을 확인함으로써, 알파-2 아드레날린 수용체 효능제를 면역관문 억제제 및 세포 표면 또는 엑소좀 PD-L1의 발현에 대한 억제제로써 암 질환의 예방 또는 치료를 증진할 수 있는 항암 효과 증진용 제제 개발에 유용하게 활용될 수 있다.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLEKAjEQRK-xEPUfFqyFM6axPA5FsBP7Y1k3uYXLJiTx_43gB1gNzLw3684ZGGNIsUiVqOBiBtYZlUQ9SAhvZUCtQq3itjnHVIGakqV8GVTAJc0IBvCVWTl7IchMnGo7Qx9VSt12K4dL4d0vN93-enmOtwOnOHFJSM2s0_1hemP6oz1ba4fTf9QHRv1AQA</recordid><startdate>20221108</startdate><enddate>20221108</enddate><creator>CHOE EUN JI</creator><creator>BAEK MOON CHANG</creator><creator>PARK JU MI</creator><scope>EVB</scope></search><sort><creationdate>20221108</creationdate><title>2 Composition for enhancing immune anticancer effect comprising an alpha 2 adrenergic receptor agonist</title><author>CHOE EUN JI ; BAEK MOON CHANG ; PARK JU MI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_KR20220149444A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; kor</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>CHOE EUN JI</creatorcontrib><creatorcontrib>BAEK MOON CHANG</creatorcontrib><creatorcontrib>PARK JU MI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHOE EUN JI</au><au>BAEK MOON CHANG</au><au>PARK JU MI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>2 Composition for enhancing immune anticancer effect comprising an alpha 2 adrenergic receptor agonist</title><date>2022-11-08</date><risdate>2022</risdate><abstract>The present invention relates to an anti-cancer effect enhancing composition comprising an alpha-2 adrenergic receptor agonist as an active ingredient. More specifically, by confirming the enhancement of anti-cancer effects in which cancer cell-derived exosome secretion is inhibited and PD-L1 expression inducing immune escape of T cells is inhibited when treating a cancer cell with the composition according to the present invention, the alpha-2 adrenergic receptor agonist may be utilized for developing an anti-cancer effect enhancing formulation for enhancing prevention or treatment of cancer, as an immune checkpoint inhibitor or an inhibitor against cell surface or exosome PD-L1 expression.
본 발명은 알파-2 아드레날린 수용체 효능제를 유효성분으로 포함하는 항암 효과 증진용 조성물에 관한 것으로, 보다 상세하게는 본 발명에 따른 조성물을 암세포에 처리하였을 때에 암세포 유래의 엑소좀 분비가 억제되고, T 세포의 면역 회피를 유도하는 PD-L1의 발현이 억제되는 항암효과가 증진되는 것을 확인함으로써, 알파-2 아드레날린 수용체 효능제를 면역관문 억제제 및 세포 표면 또는 엑소좀 PD-L1의 발현에 대한 억제제로써 암 질환의 예방 또는 치료를 증진할 수 있는 항암 효과 증진용 제제 개발에 유용하게 활용될 수 있다.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; kor |
| recordid | cdi_epo_espacenet_KR20220149444A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | 2 Composition for enhancing immune anticancer effect comprising an alpha 2 adrenergic receptor agonist |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A06%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHOE%20EUN%20JI&rft.date=2022-11-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EKR20220149444A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |